Valproic acid reprograms the metabolic aberration of cisplatin treatment via ALDH modulation in triple-negative breast cancer cells

We recently demonstrated that the histone deacetylase inhibitor valproic acid (VPA) reprograms the cisplatin-induced metabolome of triple-negative breast cancer (TNBC) cells, including a shift in hexose levels. Accordingly, here, we tested the hypothesis that VPA alters glucose metabolism in correla...

Descripción completa

Detalles Bibliográficos
Autores principales: Granit Mizrahi, Avital, Gugenheim, Ahinoam, Hamad, Haneen, Hamed, Roa’a, Tetro, Nino, Maimon, Ofra, Khutsurauli, Salome, Nechushtan, Hovav, Nisman, Benjamin, Duran, Deborah, Samman, Widad, Birimberg-Schwartz, Liron, Grunewald, Myriam, Eyal, Sara, Peretz, Tamar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Cell and Developmental Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10639136/
https://www.ncbi.nlm.nih.gov/pubmed/37954205
http://dx.doi.org/10.3389/fcell.2023.1217149

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10639136/
https://www.ncbi.nlm.nih.gov/pubmed/37954205
http://dx.doi.org/10.3389/fcell.2023.1217149

Ejemplares similares